Mannatech, Incorporated (MTEX) is a Texas-based global health and wellness company that develops and sells nutritional supplements, skin-care and anti-aging products, and weight-management lines such as Ambrotose, sold through a network-marketing model across the Americas, Asia-Pacific and EMEA. Its shares were quoted at $4.34 in Monday's session, down 31.11% from the prior close of $6.30 and the lowest level in at least four months. The move extends Friday's 29.84% decline, which itself followed the Nov. 12 quarterly release, taking the two-session loss past 50%. The direction is unambiguously negative, and the immediate cause is the market's reassessment of the company's core earnings power after a quarter that produced accounting profit but an operating loss in all but name.
The third-quarter figures were weak where it matters. Net sales of $24.9 million were $4.3 million below the prior-year period, a 14.6% constant-dollar decline with no currency benefit to flatter the comparison. Gross margin slipped 170 basis points to 74.7% as cost of sales fell more slowly than revenue. Selling and administrative expenses were trimmed 4.1% to $8.7 million, but because revenue contracted faster, that line rose to 35.0% of sales from 31.1%. The result was operating income of just $0.3 million, down from $2.0 million, a 90% decline in constant dollars.
The reported bottom line told a very different story, and the market clearly read past it. Net income of $8.9 million, or $4.61 per diluted share, versus $1.01 a year earlier, was driven by a $10.9 million non-cash income tax benefit tied to a remeasurement of deferred tax liabilities on unremitted foreign earnings. The company stated plainly that the benefit generated no cash and that quarterly net income does not reflect an improvement in operating performance. Pre-tax results were a $2.0 million loss, and a $2.1 million net foreign-currency loss replaced a $0.6 million gain a year ago. For a company of this size, a swing of this magnitude in its only meaningful profit line is a material event.
The forward-looking metrics were arguably worse than the income statement. New and continuing independent associates and preferred customers totaled roughly 111,000, down from 119,000, and recruitment of new associates and preferred customers fell 30.5% year over year. Because the direct-selling model depends on associate activity, a shrinking recruiting funnel points to further top-line pressure. Cash and equivalents ended the quarter at $5.4 million, down 12.4% since Dec. 31.
Balance-sheet optics remain a live issue. Mannatech had been operating with a stockholders' equity deficit and received a Nasdaq notice in April over the $2.5 million minimum equity requirement. Compliance was restored in October only through a non-cash accounting remeasurement tied to an internal restructuring of foreign subsidiaries, not through cash generation. That leaves the listing standard dependent on reported equity rather than operating recovery, a structure investors tend to discount heavily in micro-caps.
Activity has been elevated on the downside but the tape is extraordinarily thin. Friday's 24,900 shares were roughly 1.8 times the average daily volume of about 13,900, and Monday's opening minutes saw only a few hundred shares change hands, a footprint consistent with a shallow order book rather than institutional repositioning. With roughly 1.93 million shares outstanding and a market value near $8.4 million, small orders can move the print by double-digit percentages.
The decline is company-specific. There was no evident broad-market, sector-wide or macro catalyst behind the move, and none of Mannatech's large-cap peers in the supplements and direct-selling space faced a comparable event. Technically, the stock gapped down and closed Friday at its session low of $6.30 — a sign of persistent, buyer-less selling — and Monday's break below the $6 and $5 areas leaves the shares without nearby reference support, having undercut every level traded over the past four months.
The score runs from 0 to 100, where 0 means no meaningful news and a move that is normal for the stock, and 100 means transformative verified news accompanied by an extreme, rare price move. Mannatech's score is 65 out of 100.
The verified news was material: an 86% drop in operating income, a return to a pre-tax loss, a 30.5% fall in recruitment and a profit figure that rested entirely on a non-cash tax benefit — significant for a company this small, though not a transformative event. The price response qualifies as extreme. Monday's 31.11% decline is roughly 6.5 times the stock's average absolute daily move of about 4.8% over the past 60 sessions, and no session in that window posted a larger one-sided move before today. Material fundamentals plus an unusually outsized, low-liquidity move combine into the mid-to-upper range.
Attentive investors will watch the company's quarterly report on Form 10-Q, which had been expected around mid-November and will carry the detailed cash-flow and equity disclosures missing from the press release. Any delay in filing, or a revision to the equity cure, would reopen listing questions. The next scheduled earnings release — fourth-quarter and full-year 2026 results — is the key fundamental test, with analyst attention centered on whether constant-dollar sales decline decelerates and whether recruitment stabilizes after the 30.5% drop. Also relevant: tariff and trade-policy commentary flagged as a cost risk, the trajectory of commission and incentive expense, and whether the company's cost-reduction plan can protect operating income. Risks are concentrated and two-sided — a single quarter of improving sales trends could produce a sharp rebound in a name this thinly traded, while continued revenue erosion or a new compliance notice would pressure the shares further. There is no reliable consensus forecast to anchor expectations.
Tickeron's Trending AI Robots page highlights the trading bots performing best under present market conditions. Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but this curated section surfaces only the strongest performers rather than the full catalogue. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the featured list changes as market conditions shift. Reviewing the current lineup is a practical way to see which approaches are working right now — visit the Trending AI Robots page to explore them.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The RSI Indicator for MTEX moved into overbought territory on November 16, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +4.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where MTEX advanced for three days, in 136 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
MTEX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 109 of 122 cases where MTEX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MTEX as a result. In 92 of 117 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for MTEX turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 40 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
MTEX moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MTEX crossed bearishly below the 50-day moving average on November 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MTEX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MTEX's P/B Ratio (-3.149) is slightly lower than the industry average of (3.045). P/E Ratio (-2.074) is within average values for comparable stocks, (55.291). Projected Growth (PEG Ratio) (0.130) is also within normal values, averaging (0.741). MTEX's Dividend Yield (0.099) is considerably higher than the industry average of (0.015). P/S Ratio (0.139) is also within normal values, averaging (0.357).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. MTEX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MTEX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 67, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of nutritional supplements, topical products, and weight-management products
Industry FoodDistributors